iPSirius, a French biotechnology company that originated from INSERM and Paris Saclay University, has set its ambition on developing active cancer immunotherapy products. Their focus lies in utilizing groundbreaking induced pluripotent stem cell (iPSC) technology. iPSirius successfully developed its first therapeutic product known as IPVAC 1.0, with the objective of priming the patient's own immune system against a wide range of cancer targets.
Our vision is to improve prognosis of cancer patients by bringing transformational and valued therapies addressing metastasis and treatment resistance. This year we conducted an exploratory road trip where we engaged investors as to the indication for our first in human (FIH) clinical trial. We are currently in the planning phases for our FIH trial for IPVAC 1.0 which will be conducted in the UK.
Chief Pharma Officer
Chief Scientific Officer
Chief Medical Officer
Chief Operating Officer
Chief Financial Officer
Clinical and regulatory activities
Clinical safety and manufacture
Legal affairs and IP